In Situ Preconditioning of Human Mesenchymal Stem Cells Elicits Comprehensive Cardiac Repair Following Myocardial Infarction
Open Access
- 1 February 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (3) , 1449
Abstract
Human bone marrow-derived mesenchymal stem cells (BM-MSCs), represented as a population of adult stem cells, have long been considered as one of the most promising sources for cell-based cardiac regenerative therapy. However, their clinical use has been significantly hampered by low survival and poor retention following administration into failing hearts. Here, to improve the therapeutic effectiveness of BM-MSCs, we examined a novel therapeutic platform named in situ preconditioning in a rat myocardial infarction (MI) model. In situ preconditioning was induced by a combinatory treatment of BM-MSCs with genetically engineered hepatocyte growth factor-expressing MSCs (HGF-eMSCs) and heart-derived extracellular matrix (hdECM) hydrogel. Subsequently, our results demonstrated that in situ preconditioning with cell mixture substantially improved the survival/retention of BM-MSCs in the MI-induced rat hearts. Enhanced retention of BM-MSCs ultimately led to a significant cardiac function improvement, which was derived from the protection of myocardium and enhancement of vessel formation in the MI hearts. The results provide compelling evidence that in situ preconditioning devised to improve the therapeutic potential of BM-MSCs can be an effective strategy to achieve cardiac repair of MI hearts.Keywords
This publication has 30 references indexed in Scilit:
- A Randomized, Open-Label, Multicenter Trial for the Safety and Efficacy of Adult Mesenchymal Stem Cells after Acute Myocardial InfarctionJournal of Korean Medical Science, 2014
- Deferoxamine preconditioning potentiates mesenchymal stem cell homingin vitroand in streptozotocin-diabetic ratsExpert Opinion on Biological Therapy, 2013
- Stem Cell Engraftment and Survival in the Ischemic HeartThe Annals of Thoracic Surgery, 2011
- Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacityProceedings of the National Academy of Sciences, 2009
- Tracking cardiac engraftment and distribution of implanted bone marrow cells: Comparing intra-aortic, intravenous, and intramyocardial deliveryThe Journal of Thoracic and Cardiovascular Surgery, 2009
- Bcl-2 Engineered MSCs Inhibited Apoptosis and Improved Heart FunctionStem Cells, 2007
- Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiationMolecular Therapy, 2006
- Monitoring of Bone Marrow Cell Homing Into the Infarcted Human MyocardiumCirculation, 2005
- Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarctionThe American Journal of Cardiology, 2004
- Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGFJournal of Clinical Investigation, 2000